MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Cara Therapeutics Company Profile (NASDAQ:CARA)

Consensus Ratings for Cara Therapeutics (NASDAQ:CARA) (?)
Ratings Breakdown: 6 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $23.83 (382.46% upside)

Analysts' Ratings History for Cara Therapeutics (NASDAQ:CARA)
Show:
DateFirmActionRatingPrice TargetActions
5/6/2016Canaccord GenuityReiterated RatingBuy$30.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/6/2016Needham & Company LLCReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/23/2016Piper JaffrayReiterated RatingOverweight$23.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/20/2016Cantor FitzgeraldReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/12/2016Janney Montgomery ScottReiterated RatingBuy$23.00 -> $18.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/29/2016LaidlawLower Price TargetBuy$30.00 -> $17.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/3/2015MLV & Co.Initiated CoverageBuy$26.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/9/2014Summer StreetInitiated CoverageBuy$20.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/30/2014 forward)
Earnings History for Cara Therapeutics (NASDAQ:CARA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/8/2016        
5/5/2016Q116($0.40)($0.39)$0.03 million$0.01 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/10/2016Q4($0.33)($0.35)$0.53 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/9/2015Q315($0.27)($0.19)$1.86 million$2.40 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/10/2015Q215($0.24)($0.25)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/12/2015Q415($0.27)($0.21)$0.70 million$0.50 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/26/2015Q4($0.30)($0.18)$0.91 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/10/2014Q314($0.22)($0.29)$0.13 million$1.13 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/7/2014Q2($0.27)($0.16)$0.08 million$0.96 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/12/2014Q1($0.14)($0.22)$0.30 million$0.18 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/27/2014($0.18)($0.49)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Cara Therapeutics (NASDAQ:CARA)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividend History for Cara Therapeutics (NASDAQ:CARA)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Cara Therapeutics (NASDAQ:CARA)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
4/20/2016Frederique Ph.D. MenzaghiVPSell6,000$9.00$54,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/17/2016Ventures Vi Lp RhoMajor ShareholderBuy400,000$4.87$1,948,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/3/2016Frederique Ph.D. MenzaghiVPSell6,000$9.04$54,240.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/26/2016Michael E LewisInsiderSell7,262$10.93$79,373.66View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/6/2016Derek T ChalmersCEOSell12,500$17.22$215,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/1/2015Frederique Ph.D. MenzaghiVPSell6,000$16.21$97,260.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/2/2015Frederique Ph.D. MenzaghiVPSell6,000$14.26$85,560.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/1/2015Frederique Ph.D. MenzaghiVPSell6,000$13.95$83,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/1/2015Frederique Ph.D. MenzaghiVPSell7,000$18.63$130,410.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/18/2015Josef SchoellCFOBuy3,000$22.10$66,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/1/2015Michael E LewisInsiderSell7,262$9.50$68,989.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/19/2015Dean SlagelDirectorSell188,811$10.02$1,891,886.22View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/1/2015Michael E LewisInsiderSell7,262$9.90$71,893.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/2/2015Michael E LewisInsiderSell7,262$10.11$73,418.82View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/2/2015Michael E LewisInsiderSell7,262$10.60$76,977.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/5/2014Ventures Vi Lp RhoMajor ShareholderBuy225,818$11.00$2,483,998.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Cara Therapeutics (NASDAQ:CARA)
DateHeadline
06/29/16 10:18 AMCara Therapeutics (CARA) Commences Adaptive Phase 2/3 Trial of I.V. CR845 as CKD Treatment
06/29/16 06:00 AMCara Therapeutics Initiates Adaptive Phase 2/3 Trial of I.V. CR845 for Treatment of Chronic Kidney Disease-Associated Pruritus - [GlobeNewswire] - STAMFORD, Conn., June 29, 2016-- Cara Therapeutics, Inc., a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively ...
06/28/16 07:33 PMWhat's Ahead for Cara Therapeutics Inc After Today's Huge Increase? - Press Telegraph
06/28/16 02:23 PMCara Therapeutics, Inc. (NASDAQ:CARA) Earnings Glance and Target Price Review - Engelwood Daily
06/28/16 02:23 PMStrong Sell Calls Recommendations For Cara Therapeutics, Inc. (NASDAQ:CARA) At 0 - Investor Newswire
06/27/16 07:43 AMAre Analysts Bearish Cara Therapeutics Inc (NASDAQ:CARA) After Last Week? - Press Telegraph
06/26/16 08:13 AMCara Therapeutics Incorporated (NASDAQ:CARA) Sellers Covered 25.23% of Their Shorts - Press Telegraph
06/25/16 04:19 AMNew Broker Ratings For Cara Therapeutics Inc (CARA) - FTSE News
06/23/16 09:19 PMCara Therapeutics Inc. (NasdaqGM:CARA) Stock Momentum Hits EXTREME Weakness - CML News
06/23/16 11:05 AMGlobal Pruritus Therapeutics Market Growth, Trends, Forecast 2015 - 2020
06/21/16 02:58 PMRecently Issued Stock Ratings For Cara Therapeutics Inc (CARA) - Fiscal Standard
06/19/16 02:54 PMCara Therapeutics Inc (CARA) Analyst Price Targets For The Coming Week - Fiscal Standard
06/16/16 03:02 PMCARA THERAPEUTICS, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
06/16/16 02:04 PMCARA THERAPEUTICS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
06/13/16 02:32 PMOverview of Price Moves: XOMA Corporation (NASDAQ:XOMA) , Cara Therapeutics, Inc. (NASDAQ:CARA) - Street Updates
06/13/16 10:58 AMPfizer, Merck, Other Big Pharmas Likely to Acquire Marijuana-Based Drug Companies -
06/11/16 08:29 PMPfizer, Merck and other Big Pharma Likely to Target Companies Developing Marijuana-based Drugs
06/09/16 10:44 AMCara Therapeutics to Present Preclinical Data at June Medical Meetings - PharmiWeb.com (press release)
06/09/16 07:00 AMCara Therapeutics to Present Preclinical Data at June Medical Meetings - [GlobeNewswire] - STAMFORD, Conn., June 09, 2016-- Cara Therapeutics, Inc., a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively ...
06/07/16 11:19 AMBiotech Spotlight: GlycoMimetics Inc (NASDAQ:GLYC), Cara Therapeutics Inc (NASDAQ:CARA) and Advaxis, Inc ... - Small Cap Exclusive (press release)
06/06/16 02:53 PMCara Therapeutics Resumes Patient Recruitment for Adaptive Phase 3 Trial of I.V. CR845 in Postoperative Pain - GlobeNewswire (press release)
06/06/16 08:17 AMCara Therapeutics Resumes Patient Recruitment for Adaptive Phase 3 Trial of I.V. CR845 in Postoperative Pain - Nasdaq
06/06/16 08:17 AMBRIEF-Cara Therapeutics resumes patient recruitment - Reuters
06/06/16 06:18 AMCara Therapeutics Resumes Patient Recruitment for Adaptive Phase 3 Trial of I.V. CR845 in Postoperative Pain - [at noodls] - STAMFORD, Conn., June 06, 2016 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain ...
06/05/16 08:21 PMCara Therapeutics Incorporated (NASDAQ:CARA) Short Interest Increased By 9.73% - HNN
06/05/16 08:21 PMAfter Last Week What Do Analysts Think Of Cara Therapeutics Inc (CARA) - Share Trading News
06/05/16 10:51 AMBiotech Industry’s Stocks Get Research Review
06/03/16 09:10 PMCara Therapeutics, Inc. (NASDAQ:CARA) Stock Update & Estimates - Stock Tick Tock
06/03/16 11:40 AMCara Therapeutics Is Feeling The Pain; But Not For Long - Seeking Alpha
06/02/16 09:06 PMCara Therapeutics Inc. (CARA) Jumps 5.05% on June 02 - Equities.com - Cara Therapeutics Inc. (CARA) Jumps 5.05% on June 02Equities.comCara Therapeutics Inc. (CARA) was among the biggest gainers on the Russell 2000 for Thursday June 02 as the stock popped 5.05% to $6.45, representing a gain of $0.31 per share. Some 737,867 shares traded hands on 5,127 trades, compared with an ...and more »
06/02/16 03:10 PMApple Inc. (NASDAQ:AAPL) Down -0.48%: Cara Therapeutics Inc. (NASDAQ:CARA), Akorn, Inc. (NASDAQ:AKRX ... - KC Register - Apple Inc. (NASDAQ:AAPL) Down -0.48%: Cara Therapeutics Inc. (NASDAQ:CARA), Akorn, Inc. (NASDAQ:AKRX ...KC RegisterCara Therapeutics Inc. (NASDAQ:CARA) traded 762192 shares and its share price moved down -4.95% to close at $6.14. Company has 5.80% insider ownership. Cara Therapeutics Inc. (NASDAQ:CARA) quarterly performance is 5.50% while its year to date ...
06/01/16 09:10 PMOn The Move Biotech Stocks: Teva Pharmaceutical Industries Limited (NYSE:TEVA) , Cara Therapeutics, Inc ... - Is stories - On The Move Biotech Stocks: Teva Pharmaceutical Industries Limited (NYSE:TEVA) , Cara Therapeutics, Inc ...Is storiesIn most recently trading session on 5/31/2016, Cara Therapeutics, Inc. (NASDAQ:CARA) climbed +1.41% while traded on 1.53 million shares versus it's an average volume of 740.36 thousand shares. The company recorded the last trade with the price of ...and more »
06/01/16 11:39 AMActive Broker's Choice: Valeant Pharmaceuticals International (NYSE:VRX), Cara Therapeutics (NASDAQ:CARA ... - Street Wise Report (press release) (blog) - Active Broker's Choice: Valeant Pharmaceuticals International (NYSE:VRX), Cara Therapeutics (NASDAQ:CARA ...Street Wise Report (press release) (blog)Valeant Pharmaceuticals International, Inc. (NYSE:VRX) [Trend Analysis] moved up reacts as active mover, shares an increase 0.11% to traded at $28.45 and the percentage gap between open changing to regular change was 1.83%. Valeant Pharma (VRX) ...and more »
06/01/16 11:39 AMBuy Sell or Hold? - Cara Therapeutics Inc. (NASDAQ:CARA), Molson Coors Brewing Company (NYSE:TAP) - Beacon Chronicle - Beacon ChronicleBuy Sell or Hold? - Cara Therapeutics Inc. (NASDAQ:CARA), Molson Coors Brewing Company (NYSE:TAP)Beacon ChronicleCara Therapeutics Inc. (NASDAQ:CARA) currently has High Price Target of $30. The Low and Mean Price Targets are $17 and $23.43 respectively. These price targets are a consensus analysis of 7 brokers. When having a look at Recommendation Trends of ...and more »
05/31/16 03:07 PMTwo Buzzers within Traders Radar: Catalent, Inc. (NYSE:CTLT) , Cara Therapeutics, Inc. (NASDAQ:CARA) - Street Updates - Two Buzzers within Traders Radar: Catalent, Inc. (NYSE:CTLT) , Cara Therapeutics, Inc. (NASDAQ:CARA)Street UpdatesCara Therapeutics, Inc. (NASDAQ:CARA) after beginning at $6.25, closed at $6.37 by building up +1.92% in recent trading session. Most recent session's volume of 627.86 thousand shares lower than its average volume of 736.83 thousand shares.and more »
05/31/16 08:35 AMProQR Therapeutics N.V. (NASDAQ:PRQR) increased 6.36%: Cara Therapeutics Inc. (NASDAQ:CARA), Sprint ... - KC Register - ProQR Therapeutics N.V. (NASDAQ:PRQR) increased 6.36%: Cara Therapeutics Inc. (NASDAQ:CARA), Sprint ...KC RegisterCara Therapeutics Inc (NASDAQ:CARA)'s stock had its “buy” rating restated by equities researchers at Canaccord Genuity in a research report issued on Friday,AnalystRatings.NET reports. They currently have a $30.00 target price on the biopharmaceutical ...
05/31/16 08:35 AMStock Review and Earnings Check on Cara Therapeutics, Inc. (NASDAQ:CARA) - HNN - Stock Review and Earnings Check on Cara Therapeutics, Inc. (NASDAQ:CARA)HNNInvestors and analysts are typically super focused on company earnings numbers when they are reported. Company earnings are a good way to evaluate the company profitability. Currently, sell-side analysts are expecting Cara Therapeutics, Inc.and more »
05/31/16 08:35 AMHC Stocks Midpoint: Cara Therapeutics Inc (NASDAQ:CARA), Cooper Companies Inc (NYSE:COO) - share market updates (press release) - HC Stocks Midpoint: Cara Therapeutics Inc (NASDAQ:CARA), Cooper Companies Inc (NYSE:COO)share market updates (press release)Shares of Cara Therapeutics Inc (NASDAQ:CARA) ended Friday session in green amid volatile trading. The shares closed up +0.12 points or 1.92% at $6.37 with 627,859.00 shares getting traded. Post opening the session at $6.25, the shares hit an intraday ...Cara Therapeutics Selected to Present at the 2016 International Conference on OpioidsVirtual-Strategy Magazineall 3 news articles »
05/31/16 07:22 AMCara Therapeutics Selected to Present at the 2016 International Conference on Opioids - [at noodls] - Leading experts to discuss unique pharmacology of peripherally selective opioids to manage chronic and acute pain during opening session Company to present positive data from Phase 2a study of Oral CR845 ...
05/30/16 10:12 AMCara Therapeutics Inc (CARA) Broker Price Targets For The Coming Week - Share Trading News - Cara Therapeutics Inc (CARA) Broker Price Targets For The Coming WeekShare Trading NewsMarket analysts have recently updated their ratings and price targets on shares of Cara Therapeutics Inc (CARA). The latest reports which are currently in issue on Monday 30th of May state 0 analysts have a rating of “strong buy”, 0 analysts “buy”, 0 ...and more »
05/28/16 06:33 PMGood Setups to watch for the week ahead - click to enlarge ) Cara Therapeutics Inc (NASDAQ:CARA) could be starting another rally as there is tremendous support in the stock (short-term EMAs) and some serious buying coming in. The price has been in a bullish flag formation off its sharp rebound ...
05/25/16 10:11 AMSignificant Buzzers of Recent Trading Period: Lpath, Inc. (NASDAQ:LPTN) , Cara Therapeutics, Inc. (NASDAQ:CARA) - Street Updates - Significant Buzzers of Recent Trading Period: Lpath, Inc. (NASDAQ:LPTN) , Cara Therapeutics, Inc. (NASDAQ:CARA)Street UpdatesCara Therapeutics, Inc. (NASDAQ:CARA) after beginning at $6.21, closed at $6.19 by building up +0.65% in recent trading session. Most recent session's volume of 798.44 thousand shares greater than its average volume of 794.3 thousand shares.
05/24/16 11:52 PMCara Therapeutics Inc (CARA) Jumps 6.03% on May 23 - Equities.com - Cara Therapeutics Inc (CARA) Jumps 6.03% on May 23Equities.comCara Therapeutics Inc (CARA) was among the biggest gainers on the Russell 2000 for Monday May 23 as the stock popped 6.03% to $6.15, representing a gain of $0.35 per share. Some 595,346 shares traded hands on 3,349 trades, compared with an ...and more »
05/24/16 06:44 PMCara Therapeutics Inc Stock Faces Higher Risks Forward After Forming Multiple Bottom Chart Pattern - Wall Street Hints and News - Cara Therapeutics Inc Stock Faces Higher Risks Forward After Forming Multiple Bottom Chart PatternWall Street Hints and NewsThe stock of Cara Therapeutics Inc (CARA) shows a multiple bottoms pattern with $5.37 target or 12.00% below today's $6.10 share price. The 8 months chart pattern indicates high risk for the $176.47M company. It was reported on May, 24 by Finviz.com.
05/24/16 10:36 AMEarnings Review and Stock Rundown for Cara Therapeutics, Inc. (NASDAQ:CARA) - Wall Street Hints and News - Earnings Review and Stock Rundown for Cara Therapeutics, Inc. (NASDAQ:CARA)Wall Street Hints and NewsInvestors and analysts will be paying close attention when the company posts earnings results. Earnings numbers can provide insight into a company's overall profitability. Covering equity analysts are expecting Cara Therapeutics, Inc. (NASDAQ:CARA) to ...and more »
05/21/16 06:11 PMCara Therapeutics Inc (CARA) Jumps 5.45% on May 20 - Equities.com - Cara Therapeutics Inc (CARA) Jumps 5.45% on May 20Equities.comCara Therapeutics Inc (CARA) was among the biggest gainers on the Russell 2000 for Friday May 20 as the stock popped 5.45% to $5.80, representing a gain of $0.3 per share. Some 495,184 shares traded hands on 2,863 trades, compared with an average ...and more »
05/20/16 10:27 AMRevenue Update on Cara Therapeutics Inc(NASDAQ:CARA) - Trade Calls - Revenue Update on Cara Therapeutics Inc(NASDAQ:CARA)Trade CallsCara Therapeutics Inc(NASDAQ:CARA) announced the earnings results for Fiscal Year 2016 and Q1. The results came in during After-hours on May 5, 2016. Company reported revenue of $7.00K. Analysts estimated a revenue of $20.00K. Earnings per share ...
05/19/16 06:36 PMCara Therapeutics, Inc. (NASDAQ:CARA) One-Year Price Projection At $22.5 - Investor Newswire - Cara Therapeutics, Inc. (NASDAQ:CARA) One-Year Price Projection At $22.5Investor NewswireSell-side analysts are certain on the prospect of Cara Therapeutics, Inc. (NASDAQ:CARA) stock. As of 2016-05-18, the stock ABR stands at 1. This type of rating states that whenever a stock has a score of 5, investors should avoid investing in such stocks.and more »
05/19/16 06:06 PMETF’s with exposure to CARA Therapeutics, Inc. : May 19, 2016 -
05/18/16 08:26 AM4 Best Stocks in the Thriving Medical Marijuana Industry -
About Cara Therapeutics

Cara Therapeutics logoCara Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing chemical entities designed to alleviate pain and pruritus by focusing on kappa opioid receptors. The Company is engaged in developing product candidates that focus on the body's peripheral nervous system. Its product candidate pipeline includes I.V. CR845 for acute pain; I.V. CR845 for uremic pruritus; Oral CR845, and CR701. The Company's I.V. CR845 is an injectable version of peripheral kappa opioid receptor agonist, which is intended for the treatment of acute pain in an acute care setting. The Company is developing an oral version of CR845 for the treatment of moderate-to-severe acute and chronic pain. The Company's CR701 is a peripherally-restricted, mixed-CB1/CB2 receptor agonist that interacts with cannabinoid receptor subtypes, with no off-target activities. CR701 is in preclinical-stage of development.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: CARA
  • CUSIP:
Key Metrics:
  • Previous Close: $4.94
  • 50 Day Moving Average: $5.61
  • 200 Day Moving Average: $7.99
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $134.77M
  • Current Quarter EPS Consensus Estimate: $-1.72 EPS
Additional Links:
Cara Therapeutics (NASDAQ:CARA) Chart for Thursday, June, 30, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha